Osang Healthcare, a company specializing in in vitro diagnostics, is raising expectations for its listing by establishing a solid sales base both domestically and internationally. With sales expected to more than double this year compared to a year ago, attention is focused on the reasons behind this growth.

According to the Financial Supervisory Service's electronic disclosure system on the 16th, Osang Healthcare's sales in North America for the third quarter of this year amounted to 291.1 billion won, accounting for 86% of total sales. This sales figure stems from the company securing an order for 100 million COVID-19 self-test kits from the U.S. government by the end of last year. This is analyzed as the result of the company's proactive efforts to expand into overseas markets and conduct preemptive sales activities.

Full article : Changed Osang Healthcare doubles sales this year thanks to US promotion